References
1. Gass JD. Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment 4th ed. St. Louis: Mosby; 1997: 70-2.
2. Klein R, Klein BE et al. The five-year incidence and progression
of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology.
1997 Jan;104(1):7-21.
3. Leibowitz HM, Krueger DE et al. The Framingham eye study
monograph: an ophthalmological and epidemiological study of cataract,
glaucoma, diabetic retinopathy, macular degeneration, and visual acuity
in a general population of 2631 adults, 1973-1975. Surv Ophthalmol.
1980;24:335-610.
4. Schachat AP, Hyman L, et al. Features of age-related macular
degeneration in a black population. The Barbados Eye Study Group. Arch
Ophthalmol. 1995;113:728-35.
5. Bird AC, Bressler NM et al. An international classification and
grading system for age-related maculopathy and age-related macular
degeneration. The International ARM Epidemiological Study Group. Surv
Ophthalmol. 1995;39:367-74.
6. Anon. American Academy of Ophthalmology Website 2004. www.aao.org/public/pi/eye_health/safety/ecm_care.html.
7. Yanoff M, Duker JS. Ophthalmology 2nd ed. St. Louis: Mosby; 2004: 925-33.
8. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999;60:99-108.
9. Vrabec T, Tantri A et al. Autosomal dominant Stargardt-like
macular dystrophy: identification of a new family with a mutation in
the ELOVL4 gene. Am J Ophthalmol. 2003;136(3):542-5.
10. Michaelides M, Hunt D et al. The genetics of inherited macular dystrophies. J Med Genet. 2003;40(9):641-50.
11. Meyers SM, Grene T et al. A twin study of age-related macular degeneration. Am J Ophthalmol. 1995; 120: 757-66.
12. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291-306.
13. Kaufman PL. Alm A. Adler’s physiology of the eye-clinical application. Mosby: New York; 2003. 319-47.
14. Friedman E. The role of the atherosclerotic process in the
pathogenesis of age-related macular degeneration. Am J Ophthalmol.
2000;130:658-63.
15. Bressler NM, Bressler SB et al. The grading and prevalence of
age-related macular degeneration in Chesapeake Bay watermen. Arch
Ophthalmol. 1989;107:847-52.
16. Seddon, JM, Willett WC et al. A prospective study of cigarette
smoking and age-related macular degeneration in women. JAMA 1996 Oct 9;
276(14): 1141-6.
17. Giblin FJ. Glutathione: a vital lens antioxidant. J Ocul Pharmacol Ther. 2000 Apr;16(2):121-35.
18. Brubaker RF, Bourne WM et al. Ascorbic acid content of human
corneal epithelium. Invest Ophthalmol Vis Sci 2000 Jun;41(7):1681-3.
19. Zarbin M. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122(4):598-614.
20. Nilsson S. Sundelin S et al. Aging of cultured retinal pigment
epithelial cells: oxidative reactions, lipofuscin formation and blue
light damage. Doc Ophthalmol. 2003 Jan;106(1):13-6.
21. Miyazaki M. Nakamura H et al. Risk factors for age-related
maculopathy in a Japanese population: the Hisayama study. Brit J
Ophthalmol. 2003;87(4):469-72.
22. De la Marnierre E, Guigon B et al. Phototoxic drugs and age-related maculopathy. J Fr Ophthalmol. 2003 26(6):596-601.
23. Semba R. Dagnelle G. Are lutein and zeaxanthin conditionally
essential nutrients for eye health? Med Hypotheses 2003; 61(4):465-72.
24. Richer S, Stiles W, et al. Double-masked, placebo-controlled,
randomized trial of lutein and antioxidant supplementation in the
intervention of atrophic age-related macular degeneration: the Veterans
LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004
Apr;75(4):216-30.
25. Seddon JM, Rosner B et al. Dietary fat and risk for advanced
age-related macular degeneration. Arch. Ophthalmol. 2001
Aug;119(8):1191-9.
26. Kolb H, Fernandez E, et al. Anatomy and physiology of the retina. www.webvision.med.utah.edu. Accessed 9/2004.
27. Fatt I, Weissman B. Physiology of the Eye: An Introduction to
the Vegetative Functions. Butterworth-Heinemann: Boston; 1992: 1-14,
213-17.
28. Davson H. Physiology of the Eye. Pergamon Press: New York. 1990: 230-54.
29. Stein. Internal Medicine. Mosby: New York. 1998: 2301-2.
30. Reber F, Kasper M, et al. Alteration of the intracellular pH and
apoptosis induction in a retinal cell line by the AGE-inducing agent
glyoxal. Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):1022-32.
31. Laedwig M. Kraus H. et al. Cone dysfunction in patients with
late-onset cone dystrophy and age-related macular degeneration. Arch
Ophthalmol. 2003;121(11):1557-61.
32. Shukla M. Hydergine--a new promise in neuro-retinal disorders. Afro-Asian J. Ophthalmol. 1989;8(1):28-30.
33. Kaven C, Spraul CW et al. Thalidomide and prednisolone inhibit
growth factor-induced human retinal pigment epithelium cell
proliferation in vitro. Ophthalmologica 2001 Jul-Aug;215(4):284-9.
34. Anon. Laser photocoagulation for juxtafoveal choroidal
neovascularization. Five-year results from randomized clinical trials.
Macular Photocoagulation Study Group. Arch Ophthalmol. 1994;112:500-9.
35. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
36. Bressler NM, Bressler SB Photodynamic therapy with verteporfin
(Visudyne): impact on ophthalmology and visual sciences. Invest.
Ophthalmol. Vis. Sci. 2000 Mar; 41(3): 624-8.
37. Bressler NM, Vertporfin therapy of subfoveal choroidal
neovascularization in age-related macular degeneration: two-year
results of a randomized clinical trial including lesions with occult
with no classic choroidal neovascularization. Verteporfin in
Photodynamic Therapy report 2. Am J ophthalmol. 2002;133:168-9.
38. Beatty S, Koh H, et al. The role of oxidative stress in the
pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000
Sep-Oct;45(2):115-34.
39. Beatty S, Murray IJ et al. Macular pigment and risk for
age-related macular degeneration in subjects from a Northern European
population. Invest. Ophthalmol Vis Sci. 2001 Feb; 42(2): 439-46.
40. Bone RA, Landrum JT, et al. Lutein and zeaxanthin in the eyes,
serum and diet of human subjects. Exp Eye Res. 2000 Sep; 71(3): 239-45.
41. Bone RA, Landrum JT et al. Macular pigment in donor eyes with
and without AMD: a case-control study. Invest Ophthalmol Vis Sci. 2001
Jan; 42(1): 235-40.
42. Rapp LM, Maple SS et al. Lutein and zeaxanthin concentrations in
rod outer segment membranes from perifoveal and peripheral human
retina. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1200-9.
43. Landrum JT, Bone RA Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 2001 Jan 1;385(1):28-40.
44. Lutty G, Grunwald J et al. Changes in choriocapillaris and
retinal pigment epithelium in age-related macular degeneration. Mol
Vis. 1999 Nov 3;5:35.
45. Smith W, Mitchell P et al. Dietary fat and fish intake and age-related maculopathy. Arch Ophthalmol. 2000 Mar;118(3):401-4.
46. Colantuoni A, Bertuglia S et al. Effects of vaccinium myrtillus
anthocyanosides on arterial vasomotion. Arzneimittelforschung. 1991
Sep;41(9):905-9.
47. Bravetti G. Preventive medical treatment of senile cataract with
Vitamin E and anthocyanosides: Clinical Evaluation. Ann Ottalmol Clin
Ocul. 1989;115:109.
48. Piovella, C. Effects of ginkgo-biloba on the micro-vessels of
bulbar conjunctiva. Minerva Med. 1973 Nov 7;64(79 Suppl.):4179-86 (in
Italian).
49. Blumenthal M, Busse WR et al. The Complete German Commission E
Monographs: Therapeutic Guide to Herbal Medicines. American Botanical
Council, 1998.
50. Anon. Oligomeric proanthocyanidins (OPC). Monograph. Altern Med Rev. 2003;8(4):442-50.
51. Specht S, Organisciak DT et al. Continuing damage to rat retinal
DNA during darkness following light exposure. Photochem Photobiol. 2000
May;71(5):559-66.
52. Lopez B, Ubels JL. Artificial tear composition and promotion of
recovery of the damaged corneal epithelium. Cornea. 1993
Mar;12(2):115-20.
53. Hayes KC, Carey RE et al. Retinal degeneration associated with
taurine deficiency in the cat. Science 1975 Jun 30;188(4191):949-51.
54. Packer L Tritschler HJ et al. Neuroprotection by the metabolic
antioxidant alpha-lipoic acid. Free Radic Biol Med.
1997;22(1-2):359-78.
55. Head KA. Natural therapies for ocular disorders, part 1: diseases of the retina. Altern Med Rev. 1999;4(5):342-59.
56. Head KA. Natural therapies for ocular disorders, part 2: cataracts and glaucoma.
Altern Med Rev. 2001 Apr;6(2):141-66.
57. Blasi MA, Bovina C, et al. Does coenzyme Q10 play a role in
opposing oxidative stress in patients with age-related macular
degeneration? Ophthalmologica. 2001 Jan-Feb;215(1):51-4.
58. Feher J, Papale A et al. Mitotropic compounds for the treatment
of age-related macular degeneration. The metabolic approach and a pilot
study. Ophthalmologica. 2003 Sep-Oct;217(5):351-7.
59. Lenaz G, D'Aurelio M et al. Mitochondrial bioenergetics in aging. Biochim Biophys Acta. 2000 Aug 15;1459(2-3):397-404.
60. Anon., AREDS reports. Arch Ophthalmol. 2001.
61. Gaziano JM, Johnson EJ et al. Discrimination in absorption or
transport of beta-carotene isomers after oral supplementation with
either all-trans- or 9-cis-beta-carotene. Am J Clin Nutr.
1995;61:1248-52.
62. Bone RA, Landrum JT, Hime GW, et al. Stereochemistry of the
human macular carotenoids. Invest Ophthalmol Vis Sci. 1993 May;
34(6):2033-40.
63. Bone RA, Landrum JT, Cao Y, Howard AN, Alvarez-Calderon F.
Macular pigment response to a supplement containing meso-zeaxanthin,
lutein and zeaxanthin. Nutr Metab (Lond). 2007 May 11;4:12.
64. For the Treatment and Prevention of Macular Degeneration: By Quantum Nutritionals Power Point Presentation.
65. Bone RA, Landrum JT, Dixon Z, et al. Lutein and zeaxanthin in
the eyes, serum and diet of human subjects. Exp Eye Res. 2000
Sep;71(3):239-45.
66. Available at: http://208.106.152.110/Studies/pref-deficiency.htm. Accessed June 14, 2007.
67. Bone RA, Landrum JT, Friedes LM, et al. Distribution of lutein
and zeaxanthin stereoisomers in the human retina. Exp Eye Res. 1997
Feb;64(2):211-8.
68. Landrum JT, Bone RA. Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys. 2001 Jan 1;385(1):28-40.
69. Haines JL, Hausner MA, Schmidt S, et al. Complement factor H
variant increases the risk of age-related macular degeneration.
Science. 2005 Apr 15;308(5720):419-24.
70. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H
polymorphism in age-related macular degeneration. Science. 2005 Apr
15;308(5720):385-9.
71. Hageman GS, Anderson, DH, Johnson LV, et al. A common haplotype
in the complement regulatory gene Factor H (HF1/CFH) predisposes
individuals to age-related macular degeneration. Proc Natl Acad Sci U S
A. 2005 May 17;102(20):7227-32.
72. VEGF Inhibition Study in Ocular Neovascularization
(V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, et al.
Year 2 efficacy results of 2 randomized controlled clinical trials of
pegaptanib for neovascular age-related macular degeneration.
Ophthalmology. 2006 Sep;113(9):1508.e1-25.
73. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR;
VEGF Inhibition Study in Ocular Neovascularization Clinical Trial
Group. Pegaptanib for neovascular age-related macular degeneration. N
Engl J Med. 2004 Dec 30;351(27):2805-16.
74. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for
neovascular age-related macular degeneration. N Engl J Med. 2006 Oct
5;355(14):1419-31.
75. Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol. 2006 Oct;124(10):1478-9.
76. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol. 2006 Jul;142(1):141-3.
77. Available at: http://www.gene.com/gene/products/information/tgr/lucentis/index.jsp. -Accessed July 19, 2007.
78. Lazic R, Gabric N. Verteporfin therapy and intravitreal
bevacizumab combined and alone in choroidal neovascularization due to
age-related macular degeneration. Ophthalmology. 2007
Jun;114(6):1179-85.
79. Bressler NM, Bressler SB, Childs AL, et al. Surgery for
subfoveal choroidal neovascularization lesions of age-related macular
degeneration: ophthalmic findings: SST report no. 13. Ophthalmology.
2004 Nov;111(11):1993-2006.
80. Hawkins BS, Bressler NM, Miskala PH, et al Surgery for subfoveal
choroidal neovascularization lesions of age-related macular
degeneration: ophthalmic findings: SST report no. 11. Ophthalmology.
2004 Nov;111(11):1967-80.
Print
PDF
Email
View Health Concern
